The Ramsay Health Care (ASX:RHC) share price is down 5% in 8 days. Could it be a buy?

Could Ramsay shares be a buy today?

| More on:
A worried doctor looks through a glass door.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Ramsay Health Care Limited (ASX: RHC) share price is having a pretty decent start to this Wednesday's trading. At the time of writing, Ramsay shares are up a healthy 0.31% to $68.38 a share.

However, zooming out, and the picture isn't quite so bright. Ramsay shares are now down around 5.1% since Friday 3 September. That's a pretty nasty drop for a 12-day span.

The company is faring… ok in 2021 so far, up close to 9% year to date. It's up a rather paltry 2.7% over the past 12 months. Compared to the S&P/ASX 200 Index (ASX: XJO), this is arguably quite poor, seeing as the ASX 200 is up close to 11% in 2021 so far, and almost 26% over the past year.

So what's been happening with Ramsay that might have sparked this recent bout of volatility?

Earnings and dividends…

Well, the short answer is… not much. Ramsay has announced no major news or developments since the announcement of its FY21 earnings report last month. Just to recap, the company reported a healthy lift in earnings by 29.1% to $1.13 billion, and a 58.1% jump in statutory profit to $449 million.

Of course, those numbers are coming off a low base, since FY20 was a pretty tough year for this healthcare company. But even so, investors seem to have given their approval, seeing as the Ramsay share price remains above it's pre-earnings pricing by around 0.7% as of today.

But perhaps the single biggest reason why Ramsay has had a rough couple of weeks is the company's dividend. Last month, in addition to the metrics above, Ramsay announced a final dividend for FY21 of $1.03 a share, bringing its full-year dividend to $1.515 per share.

Ramsay traded ex-dividend for this final payout on 6 September. This caused the usual share price dip, reflecting that new shareholders will not be eligible for the payout.

This dip (which is one of the best reasons to have a share drop in value) is the primary reason why Ramsay shares have gone backwards by around 5% since 3 September. Eligible shareholders will receive this dividend on 30 September.

So could Ramsay shares be a buy at these current levels?

Could the Ramsay Health Care share price a buy today?

Well, one fund manager who thinks so is Tribeca Investment Partners fund manager Jun Bei Liu. My Fool colleague Tony interviewed Ms Liu this week, and it turns out she is very bullish on Ramsay shares right now. Here's some of what she told the Motley Fool:

Ramsay, obviously private hospitals, and elective surgery at the moment is being suspended — it's having an earnings impact. However, remember, this is infrastructure-like, private hospital assets. It used to trade at such a big premium to the market, at a premium to the other healthcare businesses.

Now it trades just over 20 times [forward P/E ratio]. The rest of the healthcare sector trades at over 40. And this is a business, structurally, things are looking better, not looking at the pandemic.

At the current Ramsay Health Care share price, this company has a market capitalisation of $15.57 billion and a dividend yield of 2.22%.

Motley Fool contributor Sebastian Bowen owns shares of Ramsay Health Care Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Up 29% this year, does Macquarie expect Medibank Private shares to continue rising?

Medibank's explosive share price growth has caught the eye of this broker.

Read more »